WELCOME to epgonline.org

Search the site for any medical term or simply browse by disease topic. Access all the information you need in one place, when you need it, how you want it and for free! 
 

Latest News

Added 2 hours ago Drug news

Supplemental application for Tresiba (insulin degludec) in hypoglycaemia submitted to FDA- Novo Nordisk

Novo Nordisk has announced the submission of a supplemental application to the FDA for including data in the label for...

Added 2 hours ago Drug news

FDA expands approval of Zykadia (ceritinib) to include patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase (ALK)-positive- Novartis

The FDA has approved the expanded use of Zykadia (ceritinib), from Novartis, to include the first-line treatment of patients with...

Added 1 day ago Drug news

Oncologic Drugs Advisory Committee recommends Endari (l-glutamine) to treat sickle cell disease.-Emmaus Life Sciences Inc.

Emmaus Life Sciences Inc. announced that the Oncologic Drugs Advisory Committee of the FDA voted 10 to 3 that the...

View all news articles

What's on the horizon?

Marshall Pearce

Cancer immunotherapies

Posted 1 month ago

It was the winner of the 1908 Nobel prize for medicine, Paul Ehrlich, who is first credited with discussing the concept of a “magic bullet”, able to target specific cells without damaging healthy tissue. With the advent of immunotherapy, as well as antibody-drug conjugates, we are beginning to realise this vision.

Marshall Pearce

Antibody-drug conjugates (ADCs)

Posted 1 month ago

Over the past couple of decades, there have been advances in a class of drugs which for a long time was purely theoretical: antibody-drug conjugates (ADCs). The concept underlying ADCs is elegant – what if it were possible to ‘target’ particular groups of cells with a cytotoxic agent, rather than exposing every cell of the body to it?

Latest Clinical Trials

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

This study involves a course of radiation to up to 5 tumors in the participant's liver followed by systemic therapy (Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body).

Added 1 month ago

A Three-part Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Secukinumab Treatment in Juvenile Idiopathic Arthritis Subtypes of Psoriatic and Enthesitis-related Arthritis

This is a double-blind, placebo-controlled, event-driven randomized withdrawal study to investigate the efficacy and safety of secukinumab treatment in the Juvenile Idiopathic Arthritis (JIA)...

Added 3 months ago

Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects (HS rPMS)

The objective of this study is to evaluate the safety profile of Adalimumab for Hidradenitis Suppurativa (HS) participants in normal medical practice.

Added 3 months ago

View all clinical trials

Latest Journal Abstracts

Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.

Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgGκ) antibody that targets signaling lymphocytic activation...

Added 4 minutes ago

Venetoclax for the treatment of patients with chronic lymphocytic leukemia.

Venetoclax is a potent, selective inhibitor of BCL-2, a key regulator of the intrinsic pathway of apoptosis. In preclinical studies, venetoclax bound to BCL-2 with high affinity and rapidly induced apoptosis...

Added 16 minutes ago

Development of venetoclax for therapy of lymphoid malignancies.

B-cell lymphoma-2 (BCL-2) family dysfunction and impairment of apoptosis are common in most B-cell lymphoid malignancies. Venetoclax (Venclexta formerly ABT-199, GDC-0199) is a highly selective BCL-2 inhibitor...

Added 24 minutes ago

View all journal articles

Latest Guidelines

American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of atherosclerosis.

The development of these guidelines is mandated by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees.

Added 3 months ago

GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD.

Since 2001, the Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease has been a valuable resource for healthcare professionals.

Added 17 days ago

Psoriasis overview NICE Pathways

This document contains a single pathway diagram and uses numbering to link the boxes to the associated recommendations.

Added 3 months ago

View all guidelines